Barclays PLC Purchases 9,854 Shares of Bioventus Inc. (NYSE:BVS)

Barclays PLC raised its position in shares of Bioventus Inc. (NYSE:BVS) by 24.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,654 shares of the company’s stock after purchasing an additional 9,854 shares during the period. Barclays PLC owned approximately 0.06% of Bioventus worth $606,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC bought a new stake in shares of Bioventus during the third quarter worth $42,000. Quest Partners LLC acquired a new stake in shares of Bioventus during the 3rd quarter valued at $51,000. Quarry LP bought a new stake in Bioventus during the 3rd quarter worth $59,000. Covestor Ltd acquired a new position in Bioventus in the 3rd quarter worth about $69,000. Finally, Mackenzie Financial Corp bought a new position in Bioventus in the second quarter valued at about $77,000. 62.94% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Katrina J. Church sold 2,535 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $26,693.55. Following the completion of the sale, the senior vice president now owns 47,264 shares of the company’s stock, valued at $497,689.92. This trade represents a 5.09 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Mark Leonard Singleton sold 10,733 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $113,018.49. Following the transaction, the chief financial officer now owns 105,162 shares in the company, valued at $1,107,355.86. The trade was a 9.26 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,054 shares of company stock worth $401,665. Company insiders own 32.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Craig Hallum boosted their price target on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, September 27th. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and boosted their target price for the stock from $12.00 to $13.00 in a report on Tuesday, December 17th. Finally, Canaccord Genuity Group raised their price target on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

Bioventus Price Performance

Shares of BVS opened at $10.11 on Friday. The business has a 50-day moving average of $10.99 and a 200-day moving average of $10.18. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The company has a market capitalization of $820.43 million, a price-to-earnings ratio of -16.57 and a beta of 0.85. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38.

Bioventus (NYSE:BVS) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. The firm had revenue of $138.96 million during the quarter, compared to analyst estimates of $132.57 million. During the same quarter last year, the business earned $0.05 EPS. As a group, equities research analysts anticipate that Bioventus Inc. will post 0.41 earnings per share for the current year.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.